Szaflarski, Jerzy P. http://orcid.org/0000-0002-5936-6627
Besson, Hervé
D’Souza, Wendyl http://orcid.org/0000-0002-1750-5131
Faught, Edward
Klein, Pavel
Reuber, Markus
Rosenow, Felix http://orcid.org/0000-0002-3989-7471
Salas-Puig, Javier
Soto Insuga, Victor
Steinhoff, Bernhard J. http://orcid.org/0000-0001-5995-5862
Strzelczyk, Adam http://orcid.org/0000-0001-6288-9915
Bourikas, Dimitrios
Daniels, Tony
Floricel, Florin
Friesen, David
Laloyaux, Cédric
Villanueva, Vicente http://orcid.org/0000-0003-2080-8042
Funding for this research was provided by:
UCB Pharma
Article History
Received: 11 December 2023
Revised: 31 January 2024
Accepted: 10 February 2024
First Online: 4 March 2024
Declarations
:
: JPS has received research funding from Biogen, Department of Defense, Eisai, GW Pharmaceuticals companies, National Institutes of Health, National Science Foundation, NeuroPace, Serina Therapeutics, Shor Foundation for Epilepsy Research, State of Alabama General Funds, and UCB Pharma; has served as a consultant or advisory board member for Elite Medical Experts, GW Pharmaceuticals, LivaNova, Lundbeck, Medical Association of the State of Alabama, NeuroPace, Serina Therapeutics, SK Life Science, and UCB Pharma; has served as an investigator on GW Research Ltd trials; and is an editorial board member for <i>Epilepsy & Behavior</i>, <i>Epilepsy & Behavior Reports</i> (editor-in-chief), <i>Folia Medica Copernicana</i>, <i>Journal of Epileptology</i> (associate editor), and <i>Journal of Medical Science</i>. HB, DB, TD, FF, VS, and CL are employees of UCB Pharma. WDS has a salary that is part-funded by The University of Melbourne; he has received travel, investigator-initiated, scientific advisory board, and speaker honoraria from UCB Pharma Australia & Global; investigator-initiated, scientific advisory board, travel, and speaker honoraria from Eisai Australia & Global; advisory board honoraria from LivaNova and Tilray; educational grants from Novartis, Pfizer, and Sanofi-Synthélabo; educational, travel, and fellowship grants from GSK Neurology Australia; and honoraria from ScieGen Pharmaceuticals; he has an equity interest in the device company Epiminder. EF has received research grants from UCB Pharma. PK has served as a consultant for Abbott, Arvelle Therapeutics, Neurelis, and SK Life Science; has been a consultant, advisory board member, and speaker for Aquestive, Eisai, Sunovion, and UCB Pharma; is a member of the medical advisory board of Stratus and the scientific advisory board of OB Pharma; is the CEO of PrevEp; and has received research support from Department of Defense/Lundbeck and CURE. MR receives payment from Elsevier as editor-in-chief of <i>Seizure</i>; and has received research grants and speaker’s fees from Eisai, LivaNova, and UCB Pharma. FR reports personal fees from Angelini Pharma, Arvelle Therapeutics, Eisai, and GW Pharmaceuticals; personal fees and other from Novartis; personal fees and grants from UCB Pharma; and grants from the Detlev-Wrobel-Fonds for Epilepsy Research Frankfurt, Deutsche Forschungsgemeinschaft, the European Union, and the State of Hessen, outside of the submitted work. JS-P has received grants from Bial and UCB Pharma; and reports personal fees from Bial, Eisai, Esteve, Sanofi, and UCB Pharma, outside of the submitted work; VSI has received speaker honoraria from Bial, Eisai, and UCB Pharma. BJS has received speaker honoraria from Al-Jazeera, Desitin, Eisai, GW Pharmaceuticals, Hikma, Novartis, Sandoz, and UCB Pharma; and has served as a consultant for Arvelle Therapeutics, B. Braun, Bial, Desitin, Eisai, GW Pharmaceuticals, and UCB Pharma. AS reports personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, GW/Jazz Pharmaceuticals, Marinus Pharma, Precisis, Takeda, UCB Pharma/Zogenix, and UNEEG Medical; and is editor-in-chief of <i>Clinical Epileptology</i> and section editor of <i>Neurological Research and Practice</i>. DF is an independent contractor working for UCB Pharma. VV has served as a consultant or on an advisory board for Angelini Pharma, Bial, Biocodex, Eisai, Jazz Pharmaceuticals, Novartis, SK Life Science, Takeda, UCB Pharma, and Xenon; has received research grants from Bial, Eisai, and UCB Pharma; and has received speaker’s honoraria from Angelini Pharma, Bial, Eisai, Jazz Pharmaceuticals, Novartis, and UCB Pharma. DB, TD, FF and CL have stocks or stock options in UCB Pharma. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
: This research study was conducted retrospectively from data obtained for clinical purposes. The EXPERIENCE database consisted of Health Insurance Portability and Accountability Act– and General Data Protection Regulation (GDPR)–compliant anonymized data; as such, no ethics committee approval was required.